Statistical issues related to the design, analysis and interpretation of carcinogenicity studies are considered. A proposed modification of the "standard" National Cancer Institute (NCI) design of carcinogenicity studies in rodents is discussed. The primary objective was to obtain a design that maintained the power of the NCI design for detecting carcinogenic effects, while increasing the precision with which the underlying dose-response model could be estimated. "Optimum" three-dose designs are presented and discussed.
This presentation deals with two important statistical issues in the interpretation of cancer bioassay data. First, the issue of experimental design is considered and recent research results obtained by Drs. Chris Portier and David Hoel of the NIEHS Biometry and Risk Assessment Program are summarized. Secondly, several important factors to keep in mind when interpreting carcinogenesis testing results are discussed. I will begin by giving a list of references upon which this presentation is based (1-4). The first two deal with issues of interpretation and are papers of mine that either have appeared or will appear in Fundamental and * Presented at the Second International Symposium of the Society of Toxicologic Pathologists, Session 11; "Statistical, Biochemical and Genetic Considerations in Protocol Design", hlay 9-11, Arlington, Virginia.
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Applied Toxicology. The second two papers are by Portier and Hoel and summarize the experimental design research that they have carried out to date.
When the National Toxicology Program reexamined the two-year carcinogenesis bioassay study in rodents, two areas were identified that required further research. The first of these was pathology, and you have already heard Dr. McConnell explain the new reduced pathology protocols being implemented by the NTP. The second area of interest was experimental design. The standard design for carcinogenicity studies developed by the National Cancer Institute in the early 1970's was directed primarily towards the goal of qualitative risk estimation, that is, toward determining whether or not a test chemical could be demonstrated to produce a carcinogenic effect in rodents. Table 1 summarizes the standard NCI carcinogenesis bioassay design that is still em-
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TOXICOLOGIC PATHOLOGY ployed in many NTP studies: three groups (maximum tolerated dose (MTD), */z MTD and controls) with 50 animals per group. Since the earljf 1970's when this design was developed, there has been an increased interest in quantitative risk estimation, that is, in the quantitative estimation of the potential cancer risk associated with a low level of exposure to the chemical under test. This interest in quantitative risk estimation led to the following research problem: Is it possible to "improve" the NCI design? Can an alternative design be derived that minimizes the variability of the low dose risk estimate (or alternatively, maximizes the accuracy of estimating the dose-response curve in the experimental region)? Can a design be found that achieves these objectives without adversely affecting the power for detecting carcinogenic effects?
The original research on this problem, has been summarized by Portier and Hoe1 (3); in this paper, they derived an experimental design which used as a criterion for an optimal design the minimization of the meansquared-error of the estimate of the virtually safe dose based on the Armitage-Doll model. The subsequent research deals not with the problem of characterizing the response in the low dose region, but rather with the problem of estimating the dose-response curve in the experimental region. One advantage of using this as a design criterion is that it has been shown that different dose-response models can agree closely in the range of observable doses, but differ by orders of magnitude in the low dose region. Thus, some investigators feel that it is preferable to optimize a design by considering model fit in the experimental -region rather than by basing it on a low dose extrapolation criterion. Although the multistage model is assumed in this effort, this is a much less critical assumption when considering the experimental region than when considering the low dose region.
To summarize briefly, the purpose of this research was to optimize two factors: (1) the power of detecting carcinogenic effects, and (2) the accuracy of estimating the dose-response curve in the observable region. The difficulty is that these two objectives are often antagonistic and thus it is a complex problem to derive a design that balances these two factors.
Consider the first factor: power. The test procedure used in the determination of power was the Cochran-Armitage linear trend test, the test traditionally used by the NCI to assess dose-response trends. This procedure has the advantage of utilizing all the available data in the statistical analysis (unlike a pairwise comparison). A design with acceptable power was defined basically as one that maintained the power of the NCI design for detecting carcinogenic effects.
The underlying statistical models used are given in Table 2 . They are three special cases of the general Armitage-Doll model: 1) the linear model, 2) the quadratic model, and 3) the linear-quadratic model. These models are quite flexible and have been found in practice to provide satisfactory fits to a wide variety of experimental data sets.
Having defined the basic structure of the models, we next consider the criterion for determining how well each model fits the data. Three different goodness-of-fit criteria were used ( Table 3 ). The first criterion (GI) attempted to estimate as accurately as possible the linear coefficient of the dose-response model. The second criterion (G 2) attempted to estimate the quadratic coefficient as accurately as possible. The third (G3) attempted to minimize the difference between the ob- Having defined the general model and the goodness-of-fit criteria used, we next considered the specific models that were employed (Table 4 ). These consisted of nine linear models, nine quadratic models, and three linear-quadratic models. The background tumor rate (P(0)) was chosen to be 0.5%, 5% or 20%. The high dose effect (P(l)-P(O)) was assumed to reflect a subtle change, a moderate change or a large change in tumor incidence. We next considered dose selection and allocation of animals. A total of 64 different designs were considered ( Table 5 ). It should be noted that this research is limited to designs involving three doses and a control. Although NCI has traditionally used onIy two doses and a control, more recent NTP studies have utilized a third dose. There are several reasons for this design modification. For example, it can be argued that intuitively one would expect that an extra dose would better characterize the dose-response curve. An additional dose also provides a safety measure in case undue toxicity is induced at the highest dose level(s). It has been shown that in certain NCI/NTP studies, particularly gavage studies, survival has been a problem at the high dose. Thus, utilizing a third dose level helps minimize the potential impact of this problem.
The first class of designs fixed the control and the high dose sample size at 50 animals per dose, fixed the middle dose at */ z MTD, and then considered various choices of the .other parameters. In the second class of models, the middle dose was raised to 0.7 MTD. Classes I11 and IV allow for greater than 50 animals in the control and high dose groups.
The three major results of this research can be summarized as follows. First, it was found that the NCI design did surprisingly well. Although it was not the optimal design, it was one of the better designs examined. The second major result was that from the standpoint of power and model fitting, there was little to be gained by utilizing a three dose design rather than a two dose design with equivalent total numbers of animals. However, one can still justify the use of an Table 2 ) were chosen to produce the responses P(0) and P(1) given above. additional dose as a safety measure to protect against an overly toxic estimate of the MTD. The third major result is the class of "globally acceptable" designs generated by this research, which is given in Table 6 . That is, these designs performed well for all goodness-of-fit criterion and still maintained the power of the NCI design for detecting carcinogenic effects. Finally, the results of this research were combined with those of the earlier study (3) involving extrapolation to produce final recommended designs ( Table  7 ). The final recommended designs were "optimal" for both extrapolation and model-fitting in the experimental dose region. NTP has initiated several studies based on HASEMAN TOXICOLOGIC PATHOLOGY this research, utilizing designs with logarithmically spaces doses (0, % MTD, 1/2 MTD and MTD) and a corresponding sample size allocation of 50, 40, 60, and 50. These sample sizes were augmented by ten animals per group to allow for an interim sacrifice at 15 months. I would now like to mention briefly three other statistical issues that I have personally been more involved with during the past several years. The first of these issues concerns the statistical methodology employed in the analysis of tumor incidence data. When b!TP assumed responsibility for the NCI carcinogenesis studies, the only statistical procedures that were routinely employed were Fisher's Exact Test for pairwise comparisons and the Cochran-Armitage trend test for dose response. In many instances these procedures will be satisfactory, but they do not take survival differences into account. NTP now routinely carries out additional procedures that adjust for intercurrent mortality. These are life-table analyses which are appropriate for lethal tumors, and Peto's Incidental Tumor Test, which is appropriate for incidental tumors. We are also studying alternative methods of analysis such as logistic regression.
NTP feels that it should report the results of both a life-table and an incidental tumor test analysis, because at present, cause of death determinations are not made on an individual animal basis. Moreover, there is apparently no concensus among pathologists regarding how accurately cause-of-death determinations can be made. As part of the new NTP pathology protocols, pathologists are being asked to ascertain whether or not, in their judgment, tumors are definitely the cause of death, may have contributed to the cause of death, were definitely not the cause of death, or whether the tumor's relationship to cause of death is unknown. It is hoped that we soon will be able to determine how realistic it is to obtain this information. The important point is that survival differences should be taken into account when evaluating differences in tumor incidence.
The second issue concerns historical controls. Over the past several years, NCI and NTP have accumulated considerable information on background tumor rates in mice and rats, particularly the B6C3Fl mouse and the Fischer 344 rat. Until recently, this information has been utilized only in a very limited way. It is the position of NTP that the concurrent control group is always the most important control group used in the decision making process. However, there are some instances in which we feel that the use of historical control data can aid an investigator in the evaluation of tumor incidence data. Two examples are rare tumors and tumors that show a marginal increase relative to concurrent controls.
Before historical control data can be used in a meaningful way, however, there are a number of problems that must first be overcome. For example, nomenclature differences must be resolved. That is, nomenclature conventions and diagnostic criteria should be identical for all studies in the historical control database. Then, criteria should be established regarding whether or not a study qualified for inclusion in the database. What studies should be included? All studies? Only the more recent studies? Only the studies at the same contract laboratory? Next, the sources of variability in historical control tumor rates must be identified, and if possible, controlled. There are certain tumors that show considerable (extra-binomial) study-to-study variability. What factors are responsible for this variability? Finally, if historical control data are to be used in a formal testing framework, statistical procedures that adjust for extra-binomial variabiltiy should be employed. Three procedures that have been proposed for taking extra-binomial variability into account (5) (6) (7) are currently being studied by the NTP. I have recently completed a manuscript (8) that considers the historical control issue in detail.
With the help of Dr. McConnell and other pathologists, NTP recently defined a new historical control database. This announcement was made in the April 1983 NTP Technical Bulletin, and tumor incidence data from this database are available upon request. This information is also contained in the manuscript mentioned above (8) .
At present NTP does not normally employ historical control data in a formal testing framework. However, the Biometry and Risk Assessment Program of the NIEHS is in the process of eva~uating the procedures mentioned earlier and will made a recommendation soon regarding which method should be used. NTP has identified two major sources of variability in historical control tumor rates: calendar year and laboratory. That is, tumor rates do seem to change over time and limiting the data base to the more recent studies helps control this source of variability. Secondly, laboratory-to-laboratory variability seems to be quite large for certain tumors. Thus, NTP currently gives primary emphasis to laboratory-specific tumor rates. The important point here is that historical control data can be useful in certain instances but there are a number of problems that must be resolved before this information can be used in a formal testing framework.
Some consideration should be given to false-positives in carcinogenicity studies, and a forthcoming publication (2) deals with this matter in some detail. First of all, it must be acknowledged that because the multiplicity of tests being carried out in the evaluation of tumor incidence data, there is a distinct possibility of finding a significant (P < .05) tumor increase by chance alone. If one were to uncritically carry out a one-sided Fisher's Exact Test at the 0.05 level for every tumor examined, then the li~elihood of at least one significant high-dose effect appears to be 8-15% for a particular sex-species group, depending upon the background tumor rates and the number of tumor sites examined. Since an NTP carcinogenicity study is ac-tualIy four exper~ments (male and female mice and rats) the probability of an overall false-positive result by this procedure is 30-40%. It should be noted that the probability of a false-positive-is limited primarily to the more common tumors since for rare tumors it is extremely unlikely that a sufficient number will occur by chance to produce a falsepositive result.
How can one guard against false;positives? One obvious answer is not to regard every P < .05 result as a biolo~ically meaningful effect. In fact, NTP believes that no rigid statistical decision rule should be the sole basis for the ultimate decision regarding a chemical's carcinogenicity. I should hasten to add that the statistical significance of a given tumor effect is perhaps the single most important consideration in the decision-making process. However, a number of other factors must be taken into account as well. These factors include 1) the historical rate of the tumor in question (is it a rare tumor or a common tumor?), 2) survival histories (how do differences in survival affect the interpretation of the data?), 3) the pattern of tumor incidence (is the effect dose related? did it occur in more than one sex-species group?) and finally, 4) the biological meaning of the effect.
We have recently completed an investigation of false-positive rates in NTP studies by examining the 25 most recent long term feeding studies. This investigation revealed that the weight of the evidence required in order for a conclusion of carcinogenicity to be made was far more than merely an isolated P < 0.05 effect. A statistical decision rule was derived that closely approximated the scientific judgment process in these studies: Declare a compound car~inogenic if any common tumor showed a significant (P < 0.01) high-dose effect or if a F < 0.05 high-dose effect occurred for an uncommon tumor. As indicated above, no rigid statistical decision rule should be the sole basis for evaluating the carcinogenicity of a chemical. However, if one wishes to estimate the false-positive rate, it should be based on a procedure that mimics closely the scientific judgment process. When the false-positive rate associated with the particular statistical decision rule mentioned above is estimated, we found that this rate was no more than 7-8% for the entire study, The point to keep in mind regarding false-positives is to be aware of the issue and not to blindly regard every P < 0.05 statistical positive as a biological positive. The statistical significance is the single most important piece of evidence, but other factors should also be considered before a final judgment is rendered regarding the carcinogenicity of a chemical.
